The clinical relevance of t(14;18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma.

The clinical relevance of t(14;18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma.
复制标题

t(14;18)/BCL-2 重排和 DEL 6q 在弥漫性大细胞淋巴瘤和免疫母细胞淋巴瘤中的临床相关性。

DOI:
10.1093/oxfordjournals.annonc.a058361
复制
发表时间:
1993
期刊:
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子:
--
通讯作者:
F. Cabanillas
F. Cabanillas
中科院分区:
--
文献类型:
--
作者:
J. Romaguera;W. Pugh;R. Luthra;A. Goodacre;F. Cabanillas

文献摘要

参考文献

被引文献

相似文献

背景 t(14; 18)/bcl-2基因重排(R)被认为是弥漫性大细胞淋巴瘤(DLCL)完全缓解率和无病生存率较差的原因。DEL 6 q也与不良结局相关。 设计 对54例进行了细胞遗传学和/或分子研究的弥漫性大细胞或免疫母细胞淋巴瘤患者进行了回顾性研究。 结果 患者特征、完全缓解率和至治疗失败时间(TTF)在3年随访时,有和无t(14;18)/BCL-2 R组相似。前者的生存率更差,但差异无统计学意义。对于DEL 6 q,有和无异常的患者在3年随访时的患者特征和生存率相似。前者的TTF更差,但无统计学显著性。 结论 本研究中t(14;18)染色体异常患者的数量与以前的报告相同或更多,但未显示t(14;18)染色体异常患者的预后更差。明确的相关性有待于进一步的患者招募和有意义的多变量分析。
BACKGROUND t(14;18)/bcl-2 gene rearrangement (R) is claimed to impart a worse rate of complete remission and disease-free survival in diffuse large cell lymphoma (DLCL). DEL 6q has also been associated with poor outcome. DESIGN Retrospective study of 54 patients with either diffuse large cell or immunoblastic lymphoma who had cytogenetics and/or molecular studies performed. RESULTS Patient characteristics, complete remission rate, and time to treatment failure (TTF) were similar at three year follow-up for groups with and without t(14;18)/BCL-2R. Survival was worse for the former but the difference was not statistically significant. For DEL 6q, patient characteristics and survival rates were similar at three year follow-up for patients with and without the abnormality. TTF was worse for the former but this was not statistically significant. CONCLUSION This study, with equal or greater number of patients with t(14;18) than previous reports, fails to show a worse prognosis for patients with the t(14;18) chromosomal abnormality. A definite association will await further accrual of patients and a meaningful multivariate analysis.
DOI: --
发表时间: 1971-11
期刊: Cancer research
影响因子: 11.2
作者:
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
通讯作者: P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
434 个连续确定的非霍奇金淋巴瘤标本的细胞遗传学分析:临床相关性。
DOI: --
发表时间: 1991
期刊: Blood
影响因子: 20.3
作者:
Offit,K;Wong,G;Filippa,DA;Tao,Y;Chaganti,RS
通讯作者: Chaganti,RS
携带t(14;18)的淋巴瘤的中高级组织学与额外的非随机染色体变化相关。
DOI: --
发表时间: 1987
期刊: Blood
影响因子: 20.3
作者:
Richardson,ME;Chen,QG;Filippa,DA;Offit,K;Hampton,A;Koduru,PR;Jhanwar,SC;Lieberman,PH;Clarkson,BD;Chaganti,RS
通讯作者: Chaganti,RS
27 名未经治疗的大细胞淋巴瘤和免疫母细胞淋巴瘤患者频繁出现非随机染色体异常。
DOI: --
发表时间: 1988
期刊: Cancer research
影响因子: 11.2
作者:
Cabanillas,F;Pathak,S;Trujillo,J;Manning,J;Katz,R;McLaughlin,P;Velasquez,WS;Hagemeister,FB;Goodacre,A;Cork,A
通讯作者: Cork,A
对具有 t(14 ; 18)(q32 ; q21) 的弥漫性大 B 细胞淋巴瘤中观察到的其他染色体异常进行分析。
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者:
Okamoto M;et. al.
通讯作者: et. al.